Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: A meta-analysis

Rijkers, Anton P.; Valkema, Roelf; Duivenvoorden, H.J.; Eijck, Casper H.J. van

doi:10.1016/j.ejso.2014.03.016

Cited by 106 publications

(50 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although computed tomography and magnetic resonance scans offer a very good anatomical definition, they are not specific enough to discriminate cancer from chronic pancreatitis and to define local infiltration of the disease and local lymph node metastasis (50). The addition of 2FDG-PET to the CT scan has been proposed to increase the sensitivity of detection of local infiltration but the results of 2FDG-PET have been very inconsistent (51), and this imaging modality is not used for staging pancreatic cancer. The use of Me4FDG, which is actively accumulated in cancer cells, has the potential to improve detection of pancreatic cancer by PET, thus allowing a better definition of the local extension of the disease and providing a better guide for the therapeutic management of the disease.…”

Section: Discussionmentioning

confidence: 99%

Functional expression of sodium-glucose transporters in cancer

Scafoglio

Hirayama

Kepe

et al. 2015

Proc. Natl. Acad. Sci. U.S.A.

230

249

View full text Add to dashboard Cite

Glucose is a major metabolic substrate required for cancer cell survival and growth. It is mainly imported into cells by facilitated glucose transporters (GLUTs). Here we demonstrate the importance of another glucose import system, the sodium-dependent glucose transporters (SGLTs), in pancreatic and prostate adenocarcinomas, and investigate their role in cancer cell survival. Three experimental approaches were used: (i) immunohistochemical mapping of SGLT1 and SGLT2 distribution in tumors; (ii) measurement of glucose uptake in fresh isolated tumors using an SGLT-specific radioactive glucose analog, α-methyl-, which is not transported by GLUTs; and (iii) measurement of in vivo SGLT activity in mouse models of pancreatic and prostate cancer using Me4FDG-PET imaging. We found that SGLT2 is functionally expressed in pancreatic and prostate adenocarcinomas, and provide evidence that SGLT2 inhibitors block glucose uptake and reduce tumor growth and survival in a xenograft model of pancreatic cancer. We suggest that Me4FDG-PET imaging may be used to diagnose and stage pancreatic and prostate cancers, and that SGLT2 inhibitors, currently in use for treating diabetes, may be useful for cancer therapy.SGLT2 | pancreatic cancer | prostate cancer | SGLT2-inhibitors P ancreatic cancer is the fourth-leading cause of cancer-related death in the United States (behind only lung, colon, and breast cancers), with 46,420 estimated new cases in 2014 and a mortality that almost equals incidence (39,590 estimated deaths in 2014); the overall 5-y survival rate is only 7% (seer.cancer.gov/statfacts/html/ pancreas.html). Prostate cancer is the most frequent cancer in men in the United States, with 233,000 estimated new cases in 2014. Despite widespread adoption of screening programs, prostate cancer is still the second-leading cause of cancer-related death in men, second only to lung cancer (seer.cancer.gov/statfacts/html/prost.

show abstract

Section: Discussionmentioning

confidence: 99%

Functional expression of sodium-glucose transporters in cancer

Scafoglio

Hirayama

Kepe

et al. 2015

Proc. Natl. Acad. Sci. U.S.A.

230

249

View full text Add to dashboard Cite

show abstract

“…However, overall survival did not differ between the three treatment groups. This study had several limitations, FDG-PET/CT may have a role in staging and survival prediction of PDAC and may add to other diagnostic information, such as that provided by histology (31). Low FDG uptake in PET scans of patients with stage I and II pancreatic cancer correlates with superior overall survival and recurrence-free survival, suggesting that glucose metabolic pathways are important in pancreatic cancer biology and that PET scan activity can be used as a prognostic biomarker after pancreatectomy (32).…”

Section: α-Smooth Muscle Actin (αSma) Expression According To Treatmementioning

confidence: 99%

Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-paclitaxel Reduces the Number of Cancer-associated Fibroblasts Through Depletion of Pancreatic Stroma

Miyashita

Tajima

Makino

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The role of PET in the diagnosis of pancreatic cancer is unclear with significant false positives and negatives 5. The improved oxygenation following methylprednisolone therapy may have related to decreased oedema and secretions such as seen when used with lymphangitis carcinomatosis 6 or to the anti‐inflammatory and tumour angiogenesis suppressive effects of corticosteroids 7.…”

Section: Discussionmentioning

confidence: 99%

Metastatic pancreatic carcinoma masquerading as cystic lung disease: a rare presentation

Stern

Huseini

Kuok

et al. 2017

Respirology Case Reports

View full text Add to dashboard Cite

This 52‐year‐old male ex‐smoker presented with a six‐month history of progressive breathlessness and weight loss. He deteriorated acutely, and was admitted with severe type 1 respiratory failure. Apart from diffuse coarse crackles on chest auscultation, physical examination was unremarkable. High‐resolution computed tomography (HRCT) showed diffuse cystic changes throughout the lungs. A diagnosis of pulmonary Langerhans cell histiocytosis (PLCH) was considered. Further workup identified a coincidental pancreatic lesion of uncertain significance, which remained indeterminate on magnetic resonance imaging (MRI) and on positron emission tomography (PET). Transbronchial biopsy revealed enteric differentiated adenocarcinoma exhibiting lepidic spread, and autopsy later confirmed primary pancreatic malignancy. This case demonstrates that metastatic pancreatic malignancy can present with severe respiratory failure and masquerade as cystic lung disease.

show abstract

Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: A meta-analysis

Cited by 106 publications

References 85 publications

Functional expression of sodium-glucose transporters in cancer

Functional expression of sodium-glucose transporters in cancer

Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-paclitaxel Reduces the Number of Cancer-associated Fibroblasts Through Depletion of Pancreatic Stroma

Metastatic pancreatic carcinoma masquerading as cystic lung disease: a rare presentation

Contact Info

Product

Resources

About